The COVID-19 pandemic has created an urgent need to develop a safe and effective vaccine. Currently, research groups around the world are working to develop more than 90 investigational vaccine candidates. While several vaccine candidates are already being tested in clinical trials, there are still critical unanswered questions around the expected clinical effectiveness of immunization. How long will protection last? What inoculation dose and regimen is needed? Which vaccine platform will provide optimal comparative effectiveness (classical strategies of weakened viral particles or components versus the various RNA and DNA vaccine strategies)?
How do we accelerate bringing a vaccine to patients?
Model-informed drug discovery & development (MID3 or modeling and simulation) has become crucial to answering scientific and regulatory questions for drugs. It is also an important approach for selecting and optimizing the most promising vaccine candidates to advance further clinical development and subsequent manufacturing.
To learn more, please visit us at